Targeted attack: new method pumps Immune-Boosting drug directly to liver tumors
NCT ID NCT05220722
Summary
This early-phase study tested a new way to treat advanced liver cancer. It delivered an experimental immune-stimulating drug (SD-101) directly into the liver's main artery, sometimes combined with standard immunotherapy drugs given by IV. The goal was to see if this targeted approach was safe and could help control the cancer in patients whose disease had progressed after one prior treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University
New York, New York, 10032, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.